Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
QazCovid-in
- Development stage
- Phase 3
- Lead developer
- Research Institute for Biological Safety Problems
- Modality
- Whole Inactivated Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
QazCovid-in is an inactivated whole virion vaccine developed for the prevention of COVID-19, caused by the SARS-CoV-2 virus. The vaccine was created using a SARS-CoV-2 strain isolated from clinical samples in Kazakhstan, which was grown in Vero cell culture, inactivated with formaldehyde, purified, concentrated, and adsorbed onto aluminum hydroxide as an adjuvant. It is administered intramuscularly as a two-dose regimen spaced 21 days apart. Developed by the Research Institute for Biological Safety Problems (RIBSP) of Kazakhstan, it demonstrated high safety and immunogenicity in preclinical studies and early-phase clinical trials[1][2][3]. The vaccine can be stored at standard refrigeration temperatures (2–8°C), facilitating distribution[3].
- Brand names
- QazVac
- Other names
- QazVacQazCoVac-P
02
Targets
SARS-CoV-2 spike protein (non-ACE2-binding motif epitopes)RBD (SARS-CoV-2 spike receptor-binding domain)N (Nucleocapsid protein)
Beyond the preview
Go deeper on QazCovid-in.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on QazCovid-in.